EB-101 Surgical application of RDEB wounds

Phase 3Active

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Epidermolysis Bullosa

Conditions

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB

Trial Timeline

Apr 2, 2023 → Sep 30, 2025

NCT ID

NCT05725018

About EB-101 Surgical application of RDEB wounds

EB-101 Surgical application of RDEB wounds is a phase 3 stage product being developed by Abeona Therapeutics for Epidermolysis Bullosa. The current trial status is active. This product is registered under clinical trial identifier NCT05725018. Target conditions include Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB.

What happened to similar drugs?

0 of 6 similar drugs in Epidermolysis Bullosa were approved

Approved (0) Terminated (1) Active (5)

🔄KB803 + PlaceboKrystal BiotechPhase 3

🔄Topical Beremagene GeperpavecKrystal BiotechPhase 3

🔄Open Label Topical Beremagene Geperpavec (B-VEC)Krystal BiotechPhase 3

🔄SD-101-6.0 cream + Placebo (SD-101-0.0) creamAmicus TherapeuticsPhase 3

❌SD-101-6.0 creamAmicus TherapeuticsPhase 3

🔄EB-101Abeona TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05725018	Phase 3	Active	Apr 2, 2023	Sep 30, 2025	Epidermolysis Bullosa

Competing Products

13 competing products in Epidermolysis Bullosa

See all competitors

Product	Company	Stage	Hype Score
Efgartigimod	Argenx	Phase 1/2	36
KB803 + Placebo	Krystal Biotech	Phase 3	44
Topical beremagene geperpavec + Placebo gel	Krystal Biotech	Phase 1/2	29
Topical Beremagene Geperpavec	Krystal Biotech	Phase 3	37
Open Label Topical Beremagene Geperpavec (B-VEC)	Krystal Biotech	Phase 3	37
SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%)	Amicus Therapeutics	Phase 2	32
SD-101-6.0 cream + Placebo (SD-101-0.0) cream	Amicus Therapeutics	Phase 3	37
SD-101-6.0 cream	Amicus Therapeutics	Phase 3	29
SD-101 dermal cream (6%)	Amicus Therapeutics	Phase 2	24
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets	Abeona Therapeutics	Phase 1/2	22
EB-101	Abeona Therapeutics	Phase 3	30
VPD-737	Vyne Therapeutics	Phase 2	25
Serlopitant Tablet + Placebo Oral Tablet	Vyne Therapeutics	Phase 2	25